Intelligent Bio Solutions Reports 47.6% Revenue Growth but Faces Increased Net Loss in Latest Quarter

Intelligent Bio Solutions Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending December 31, 2025. The company generated revenue of $896,774 for the three months ended December 31, 2025, marking a 47.6% increase from $607,494 in the same period of the previous year. For the six-month period, revenue rose to $2,008,571, up 35.6% from $1,479,781 year-over-year. Despite this growth, the company reported a net loss of $2,686,613 for the quarter, compared to a loss of $2,256,797 in the prior year, and a six-month net loss of $5,681,605, up from $4,951,596.

The company’s operational metrics indicate a positive trend in customer acquisition, with 17 new customers added in the latest quarter and a total of 49 new customers in the six-month period. This growth in customer count contributed to an increase in the ongoing reorder rate for consumables. However, the cost of revenue also increased, driven primarily by higher direct labor costs due to annual salary revisions. The gross profit for the quarter was $459,739, a substantial increase from $223,113 in the previous year, resulting in a gross margin improvement to 48.69% from 38.51%.

Strategically, Intelligent Bio Solutions has made notable advancements, including a new manufacturing partnership with Syrma Johari MedTech Ltd. aimed at scaling production of its Intelligent Fingerprinting Drug Screening Reader. This partnership is expected to yield annual production cost savings of over 40%. Additionally, the company entered a strategic alliance with Vlepis Pty Ltd. to enhance its position in the consumer health monitoring market. These initiatives are part of a broader strategy to expand market share in the UK and Europe, as well as to penetrate the Asia Pacific region.

Despite these positive developments, the company faces challenges, particularly regarding liquidity. As of December 31, 2025, Intelligent Bio Solutions had cash and cash equivalents of $740,371 and a subscription receivable from shareholders of $9,402,105, which was received on January 2, 2026. However, management expressed concerns that these funds may be insufficient to support operations for the next 12 months, necessitating additional capital raises. The company has indicated plans to pursue equity or debt financing, but there are no guarantees that such funding will be available on favorable terms.

Looking ahead, Intelligent Bio Solutions aims to continue its focus on product development and market expansion, particularly in regulatory approvals for its products in the U.S. and other markets. The company is also working to enhance its operational efficiencies and sales mix to drive sustainable profit improvements. However, the ongoing need for additional funding and the potential risks associated with its operational plans remain critical factors for the company's future performance.